Ironwood Pharmaceuticals has acquired 1 company, including 1 in the last 5 years.
Ironwood Pharmaceuticals’ largest acquisition to date was in 2023, when it acquired VectivBio AG for $1.0B. The Company’s most targeted sectors include life science (100%).
100 Summer Street, Suite 2300,
Boston, Massachusetts
02110
United States,
(617) 621-7722
www.ironwoodpharma.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
||
|---|---|---|---|---|---|---|---|---|
| 2023-05-22 |
VectivBio · Life Science
Basel, Switzerland · www.vectivbio.com VectivBio is a clinical-stage biotechnology company focused on rare diseases with well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. VectivBio is based in Basel, Switzerland.
|
1,000
37.0x REVENUE |
Add-on Acquisition |
Ironwood Pharmaceuticals
|
- |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
